Multicenter study for brain/body hypothermia for hypoxic–ischemic encephalopathy: Changes in HMGB ‐1
2017; Wiley; Volume: 59; Issue: 10 Linguagem: Inglês
10.1111/ped.13377
ISSN1442-200X
AutoresToshihiko Nakamura, Hideomi Asanuma, Satoshi Kusuda, Ken Imai, Shigeharu Hosono, Ryota Kato, Satoshi Suzuki, Kyoko Yokoi, Minoru Kokubo, Shingo Yamada, Takashi Kamohara,
Tópico(s)Heart Rate Variability and Autonomic Control
ResumoAbstract Background We measured changes in the blood level of high‐mobility group box‐1 ( HMGB ‐1) at 24 h intervals in neonates treated with brain/body hypothermia (body hypothermia therapy: BHT ) for hypoxic–ischemic encephalopathy ( HIE ), to evaluate the usefulness of HMGB ‐1 level for determining outcomes. Methods We studied 15 neonates with HIE who underwent BHT ( BHT (+) group) and six neonates with HIE who did not ( BHT (–) group). We recorded HMGB ‐1 changes at 24 h intervals, creatinine phosphokinase, and the resistance index of the anterior cerebral artery. Magnetic resonance imaging ( MRI ) was used to determine short‐term outcome. Result Baseline HMGB ‐1 was significantly higher in the BHT (+) group than in the BHT (–) group. Thereafter, HMGB ‐1 in the BHT (+) group significantly decreased at 24 h intervals, reaching the reference range by 2 days of age. In the BHT (+) group, when patients were classified into clinically significant neurological disorder due to HIE (+) and (–) according to MRI , the neurological disorder (+) group had higher mean HMGB ‐1. Conclusions In HIE , HMGB ‐1 differs according to the presence of BHT , suggesting that HMGB ‐1 measurement soon after birth might be useful for determining BHT necessity and short‐term outcome.
Referência(s)